康缘药业(600557) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥814,490,717.88, representing a year-on-year increase of 12.50%[7]. - The net profit attributable to shareholders for the same period was ¥47,611,392.31, reflecting a growth of 9.46% compared to the previous year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,155,710.50, which increased by 20.62% year-on-year[7]. - Net profit for the third quarter of 2021 was ¥210,413,540.55, compared to ¥194,022,953.41 in the same quarter of 2020, representing an increase of 8.46%[38]. - The company's total comprehensive income for the third quarter of 2021 was ¥210,413,540.55, compared to ¥194,022,953.41 in the same quarter of 2020, showing an increase of 8.46%[38]. - The profit before tax of ¥250,211,573.06 for the third quarter of 2021, compared to ¥231,978,991.29 in the same quarter of 2020, reflecting an increase of 7.87%[35]. Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.08, unchanged from the previous quarter, while the diluted earnings per share was also ¥0.08[10]. - Earnings per share for the third quarter of 2021 were ¥0.36, up from ¥0.33 in the same quarter of 2020[39]. Assets and Liabilities - The total assets as of September 30, 2021, amounted to ¥5,750,411,853.81, a decrease of 6.02% compared to the end of the previous year[10]. - The total liabilities of the company were RMB 1,389,138,496.68, down from RMB 1,791,779,701.68, representing a decrease of approximately 22.5%[30]. - The company's non-current assets totaled RMB 3,143,257,809.79, a decrease from RMB 3,232,817,716.58[30]. - The company reported a total current liabilities of RMB 1,296,304,409.45, down from RMB 1,696,041,749.78, indicating a decrease of approximately 23.6%[30]. Cash Flow - The company reported a net cash flow from operating activities of ¥683,361,113.13 for the year-to-date, which increased by 10.60%[10]. - The net cash flow from operating activities for the first three quarters of 2021 was RMB 683,361,113.13, an increase of 10.6% compared to RMB 617,878,433.46 in the same period of 2020[42]. - Total cash inflow from operating activities was RMB 3,367,959,216.39, up from RMB 3,066,760,714.59, reflecting a growth of 9.8% year-over-year[42]. - Cash outflow from operating activities totaled RMB 2,684,598,103.26, compared to RMB 2,448,882,281.13 in the previous year, indicating an increase of 9.6%[42]. - The net cash flow from investing activities was negative at RMB -233,639,277.64, worsening from RMB -142,491,641.09 in the same period last year[43]. - The net cash flow from financing activities was negative at RMB -438,458,725.39, compared to RMB -266,057,236.82 in the previous year, indicating a decline[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,572[16]. - The largest shareholder, Jiangsu Kangyuan Group Co., Ltd., held 176,173,467 shares, accounting for 29.71% of the total shares[16]. - The company held 16,452,086 shares in its repurchase account as of September 30, 2021[10]. - The company had a repurchase account holding 16,452,086 shares as of September 30, 2021, which is not included in the top ten shareholders[23]. Research and Development - Research and development expenses for the first three quarters of 2021 totaled ¥336,806,040.18, compared to ¥286,790,684.86 in 2020, indicating a year-on-year increase of 17.43%[35]. Equity - The total equity attributable to shareholders of the parent company as of the end of the reporting period was ¥4,193,860,637.19, up from ¥4,166,603,588.38 at the end of 2020[32]. - The minority shareholders' equity increased to ¥167,412,719.94 from ¥160,125,085.46 in the previous year[32].